• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5081103)   Today's Articles (1144)
For: Knöchel J, Nilsson C, Carlsson B, Wernevik L, Hofherr A, Gennemark P, Jansson‐Löfmark R, Isaksson R, Rydén‐Bergsten T, Hamrén B, Rekić D. A case-study of model-informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II. CPT Pharmacometrics Syst Pharmacol 2022;11:1569-1577. [PMID: 36126230 PMCID: PMC9755919 DOI: 10.1002/psp4.12866] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Revised: 09/01/2022] [Accepted: 09/05/2022] [Indexed: 11/09/2022]  Open
Number Cited by Other Article(s)
1
Choi GW, Kim JH, Kang DW, Cho HY. A journey into siRNA therapeutics development: A focus on Pharmacokinetics and Pharmacodynamics. Eur J Pharm Sci 2025;205:106981. [PMID: 39643127 DOI: 10.1016/j.ejps.2024.106981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2024] [Revised: 12/02/2024] [Accepted: 12/03/2024] [Indexed: 12/09/2024]
2
Mercier AK, Ueckert S, Sunnåker M, Hamrén B, Ambery P, Greasley PJ, Åstrand M. From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials. Clin Pharmacol Ther 2024;116:653-664. [PMID: 38961664 DOI: 10.1002/cpt.3362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2024] [Accepted: 06/16/2024] [Indexed: 07/05/2024]
3
Madabushi R, Benjamin J, Zhu H, Zineh I. The US Food and Drug Administration's Model-Informed Drug Development Meeting Program: From Pilot to Pathway. Clin Pharmacol Ther 2024;116:278-281. [PMID: 38445751 DOI: 10.1002/cpt.3228] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Accepted: 02/07/2024] [Indexed: 03/07/2024]
4
Clewe O, Rekić D, Quartino AL, Carlsson B, Higashimori M, Wernevik L, Hofherr A, Rydén-Bergsten T, Nilsson C, Knöchel J. Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide. Br J Clin Pharmacol 2024;90:1503-1513. [PMID: 38504437 DOI: 10.1111/bcp.16046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Revised: 02/06/2024] [Accepted: 02/18/2024] [Indexed: 03/21/2024]  Open
5
Agnello F, Ingala S, Laterra G, Scalia L, Barbanti M. Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management. J Clin Med 2024;13:1251. [PMID: 38592091 PMCID: PMC10931739 DOI: 10.3390/jcm13051251] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2024] [Revised: 02/09/2024] [Accepted: 02/20/2024] [Indexed: 04/10/2024]  Open
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA